Advances and Progress in Drug Design - Discover the latest developments
/EINPresswire.com/SMi are proud to present the 11th annual Advances and Progress in Drug Design conference, taking place on 20th & 21st February 2012 at Copthorne Tara Hotel in London, UK. The number of pharmaceutical products entering the market has declined in the last decade. With the economic downturn and increasing threat from generic companies, pharmaceutical companies have never been under greater pressure to develop new innovative drugs. Many pharmaceutical and biotechnology companies are now searching for effective strategies to improve hit-to-lead conversion and to identify unsuccessful compounds early in the development process.
SMi's Drug Design Conference will aim to address many of the challenging issues faced by the pharmaceutical industry in drug design. Key selected industry experts will provide you with timely and up-to-date information on many areas of drug design.
Why you should attend this conference
• Understand key strategies to increase the clinical success of your product
• Evaluate the design of allosteric modulators for the treatment of CNS disorders
• Discuss protein-protein interactions
• Identify novel targets in drug discovery
• Hear the latest in rational drug design
• Understand how computational tools can be used to reduce drug toxicity
• Use this as a platform to further your understanding of this field
Speakers presenting at this year's event include...
• Mike Hann, Director of Bio-Molecular Structure, GSK
• Jerome Amaudrut, Senior Scientist in Computer-Aided Drug Design, Abbott
• John Mathias, Head of Medicinal Chemistry - Inflammation & Remodelling, Pfizer
• Matthias Frech, Head of Molecular Interaction & Biophysics, Merck
• Suvit Thaisrivongs, Vice President, Discovery Chemistry, Pfizer
Visit our website here: http://www.smi-online.co.uk/2012drugdesign20.asp
Alternatively contact Andrew Gibbons on +44 (0) 20 7827 6156 or e-mail: agibbons@smi-online.co.uk
SMi's Drug Design Conference will aim to address many of the challenging issues faced by the pharmaceutical industry in drug design. Key selected industry experts will provide you with timely and up-to-date information on many areas of drug design.
Why you should attend this conference
• Understand key strategies to increase the clinical success of your product
• Evaluate the design of allosteric modulators for the treatment of CNS disorders
• Discuss protein-protein interactions
• Identify novel targets in drug discovery
• Hear the latest in rational drug design
• Understand how computational tools can be used to reduce drug toxicity
• Use this as a platform to further your understanding of this field
Speakers presenting at this year's event include...
• Mike Hann, Director of Bio-Molecular Structure, GSK
• Jerome Amaudrut, Senior Scientist in Computer-Aided Drug Design, Abbott
• John Mathias, Head of Medicinal Chemistry - Inflammation & Remodelling, Pfizer
• Matthias Frech, Head of Molecular Interaction & Biophysics, Merck
• Suvit Thaisrivongs, Vice President, Discovery Chemistry, Pfizer
Visit our website here: http://www.smi-online.co.uk/2012drugdesign20.asp
Alternatively contact Andrew Gibbons on +44 (0) 20 7827 6156 or e-mail: agibbons@smi-online.co.uk
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.